Recent 8-K filings for AEMD

• February 23, 2026, 6:59 PM ET other material materiality 0.60 neutral item 5.02item 5.07item 5.03item 9.01 ◈ Governance Changes

  Aethlon Medical stockholders approve increase in authorized shares to 100M and equity plan amendment

  Stockholders approved increase in authorized common shares from 6M to 100M (495,950 for, 58,624 against).

• December 8, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.03item 7.01item 9.01

  Aethlon Medical prices $3.3M PIPE and warrant inducement at $4.03/unit

  Gross proceeds ~$3.3M from private placement and warrant inducement; closing expected Dec 8, 2025.

• November 12, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances

  Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.

• November 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Aethlon Medical regains Nasdaq minimum bid price compliance, matter closed

  Received Nasdaq letter on Nov 5, 2025 confirming regained compliance with $1.00 minimum bid price rule.

• October 22, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

  Aethlon Medical receives Nasdaq delisting notice for bid price below $1.00, requests hearing, implements reverse split

  Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.

• October 16, 2025, 7:59 PM ET other material materiality 0.75 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Aethlon Medical (AEMD) files 1-for-10 reverse stock split effective Oct 16, 2025; split-adjusted trading Oct 20

  Reverse split effective 10:00 a.m. ET Oct 16, 2025; split-adjusted trading begins Oct 20 under symbol AEMD.

• September 9, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Aethlon Medical prices $4.5M public offering of common stock and warrants at $0.90/unit

  Gross proceeds of $4.5M; net to company ~$3.9M after placement agent fees and expenses.

• August 13, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort

  Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.

• June 27, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients

  Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.

• March 17, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 3.03item 9.01

  Aethlon Medical raises ~$2.3M via warrant exercise inducement, issues new warrants

  Gross proceeds of approximately $2,316,320 from exercise of 6,200,000 Existing Warrants at reduced price of $0.3736/share.

• December 20, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak

  In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial

  Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.

• November 12, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors

  First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.

• August 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial

  Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.

• August 12, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia

  Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.

• June 27, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved

  Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.

• May 17, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Aethlon Medical prices $4.7M public offering of common stock and warrants at $0.58 per unit

  Gross proceeds ~$4.7M; net proceeds ~$3.84M after placement agent fees and expenses.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.57 · Most common event other_material

6 positive 1 negative 27 neutral

source · AEMD on sec.gov